报价延迟最少15分钟:2026/01/07 23:18 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.46 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-8.72/-1.57
|
|
企业价值
16.20M
|
| 资产负债 |
|
每股账面净值
1.17
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. |
